Nuformix PLC NXP004 Update (5387Q)
June 29 2022 - 1:00AM
UK Regulatory
TIDMNFX
RNS Number : 5387Q
Nuformix PLC
29 June 2022
29 June 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
NXP004 Update
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to provide an update in relation to the
Company's NXP004 programme, focused on the development of novel
physical forms of olaparib. Olaparib is currently marketed by
AstraZeneca, under the Lynparza(R) brand name. Lynparza(R) was
first approved in December 2014 for the treatment of adults with
advanced ovarian cancer and deleterious or suspected deleterious
germline BRCA mutation. Since then, Lynparza(R) has secured similar
approvals in breast, pancreatic and prostate cancers with further
trials on-going. These approvals have propelled Lynparza(R) sales
to US$2.7bn in 2021, with industry analysts forecasting annual
sales of US$9.7bn by 2028.
Olaparib is known to present significant challenges in achieving
effective oral delivery. In August 2017, AstraZeneca secured
approval for a new formulation of Lynparza(R) which sought to
address such challenges. The Company has previously demonstrated
the enhanced performance of NXP004 cocrystals compared to olaparib.
Further preformulation studies have allowed the Company to identify
lead cocrystals from its patent estate to be progressed for further
development.
The Company is pleased to report that it has initiated a
programme of work to progress the NXP004 programme in three key
areas:
-- Commence the scale-up of lead cocrystal production processes;
-- Directly compare in-vitro dissolution performance of lead
co-crystals to the marketed Lynparza (R) product; and
-- Based on the results from these studies a formulation
development programme may be initiated. The aims of this work will
be to develop prototype formulations that offer the potential to be
both bioequivalent and 'bio-better' versus the Lynparza (R)
product.
Further updates will be announced in due course, as
appropriate.
Commenting, Dr Julian Gilbert, Non-executive Director of
Nuformix, said: " The strategy of the Group is to continue to
optimise value from its existing assets while maintaining tight
control of costs. We believe that NXP004 has considerable
commercial potential and the work we are now undertaking is
designed to formulate our lead co-crystals towards a product form
suitable for human use. This work will direct and support future
out-licensing discussions for NXP004. I look forward to providing
further updates in due course as we progress."
Enquiries:
Nuformix plc
Dr Julian Gilbert, Non-executive Via IFC Advisory
Director
Maddy Kennedy, Non-executive Director
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDQVLFLLQLXBBK
(END) Dow Jones Newswires
June 29, 2022 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024